Tyler W. Jenkins, PhD

Postdoctoral Research Trainee
Vanderbilt Univ. Med. Ctr., United States

Disclosure information not submitted.

Presentation(s):

• BA1 - Rewriting Autoimmunity: New Immunologic Insights Transforming T1D Therapy Development, Sponsored by Breakthrough T1D

  Thursday, April 16, 2026
  7:00 AM - 8:00 AM US ET

• The antigen-specific immunotherapy, AKS-107, selectively depletes anti-insulin B lymphocytes in the pancreas and reduces insulitis in T1D-prone mice

  Thursday, April 16, 2026
  8:45 AM - 9:00 AM US ET